Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs NextEra Energy, Inc. (NEE) Price & Performance

Adaptive Biotechnologies CorpTrade
NextEra Energy, Inc.Trade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs NextEra Energy, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while NextEra Energy, Inc. trades at $85.73 (market cap $176.68B). The key difference: NextEra Energy, Inc. is far larger — about 43.6× Adaptive Biotechnologies Corp's market cap, and NextEra Energy, Inc. pays a 2.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTNEE
Market Cap
$4.05B$176.68B
Sector
HealthUtilities
52-Week High
$25.45$97.88
52-Week Low
$12.30$69.77
Enterprise Value
$4.12B$284.01B
Dividend Yield
2.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

NextEra Energy, Inc.

NextEra Energy (NEE) trades at $84.65, showing minimal daily movement with a 0.06% gain. The stock is in a bearish technical phase, with support at $84 and resistance at $86. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. The company benefits from strong AI-driven power demand, highlighted by a $100 billion data center project in Kentucky announced on July 29, 2026 (Reuters).

NEE offers solid fundamentals with a 32.4% net income margin and 17.23% ROE, but faces risks from high debt levels and capital expenditures. Analysts are bullish with a $101.17 consensus price target, implying 19% upside. Key opportunities include AI infrastructure growth, while risks involve execution on large projects and interest rate sensitivity.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About NextEra Energy, Inc.

NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.

Read more on NEE